The elevated levels of four membrane protein biomarkers in melanoma plasma EVs, melanoma chondroitin sulfate proteoglycan (MCSP), melanoma cell adhesion molecule (MCAM), low-affinity nerve growth factor receptors (LNGFR), and receptor tyrosine protein kinase and ErbB3 may predict resistance to B-Raf proto-oncogene serine/threonine kinase (BRAF) inhibitor therapy in melanoma patients [97]. This evidence concerns the gene BRAF and melanoma.